LONDON – Owkin Inc. added a further $18 million to its series A, bringing the amount raised in the round to $70 million and equipping the company to push forward with its federated learning approach to applying artificial intelligence (AI) to the analysis of health data.
TORONTO – Industry-led accelerator Next Generation Manufacturing Canada (NGen) has dipped into its CA$50 million (US$37 million) supercluster fund to help three Canadian companies beef up the nation’s supply of COVID-19 equipment and medical devices.
Evidation Health Inc. reported good news this week in the form of the close of $45 million in series D funding, with an eye toward the expansion of its research platform, Achievement, to include virtual health. B Capital Group led the round, with Mckesson Ventures and Section 32 joining, in addition to existing investors Revelation Partners, Rethink Impact and SV Health Investors.
Bolt Biotherapeutics Inc.’s $93.5 million series C round “takes us well into the back end of 2021 and into 2022,” CEO Randall Schatzman told BioWorld, with enough money that the firm is “not impeded in terms of the creativity [we’re] bringing to the table.”
PERTH, Australia – Melbourne-based Neuren Pharmaceuticals Ltd. will be able to progress NNZ-2591 to the clinic for three orphan indications after raising AU$20 million (US$13.75 million) in a placement to institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the U.K.